COVID-19

Updated April 17, 2020

At Retrophin, we are brought together by our mission of identifying, developing and delivering life-changing therapies to people living with rare disease. As we face the challenges presented by the coronavirus (COVID-19), the continued pursuit of this mission is ever more important.

We extend our thoughts and well wishes to the individuals and communities who have already been affected. The health and safety of our employees, patients and caregivers remains our top priority. We recognize that this situation continues to evolve, and we are following guidance from the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), as well as local public health authorities.

We have implemented proactive measures in an effort to best safeguard our employees and organization so that our work on behalf of patients can continue. These include travel restrictions and a remote work environment.

Access to Medications

Our teams and partners are working diligently to ensure continued access and support for patients receiving our approved therapies. We have taken steps, including access to additional inventory and flexible shipping options, to maintain continued delivery through this situation. The Total Care HUB is fully staffed and available to work with patients should they have product questions, need assistance with insurance verification, reimbursement options, or financial support during this period. Patients currently prescribed a Retrophin therapy who have a question should speak to their healthcare professional or contact the Total Care Hub.

Clinical Trials

We are thankful to those participating in our clinical trials, as well as our clinical investigators and study site staff – all of whom are partners in potentially bringing life-changing therapies to children and adults living with rare disease.

We continue to prioritize the safety of our clinical trial participants and we are working closely with our principal investigators, participating physicians and individual sites to establish best practices during this situation. Patients who have any questions about our clinical studies should reach out directly to their treating physician or study site.

We know that rare diseases do not wait for pandemics like coronavirus, and our organization remains steadfast in its dedication to serving our patients and caregivers. We are continuously inspired by the rare disease community and we are thankful for the ongoing collaboration of our partners, patient advocates, clinical investigators, healthcare providers and the many others who are all coming together to support patients and their families during this period.

We wish you, your organization and community well. By embracing our global interconnectedness and helping others during this challenging time, we will ultimately emerge from this situation as a stronger community.

Take care and stay safe,

Eric Dube, Ph.D.
President and CEO
Retrophin, Inc.